Floatz logo

GLUCOSE, ANHYDROUS

Monoclonal Gammopathy of Undetermined Significance

Mayo ClinicSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Monoclonal Gammopathy of Undetermined Significance cohort.

Asset / SponsorPhaseRating
Dfn-15
National Cancer Institute (NCI)
Phase 2B
Isatuximab
Assistance Publique - Hôpitaux de Paris
Phase 2CCC
Metformin
Dana-Farber Cancer Institute
Phase 2CCC
Linvoseltamab
Regeneron Pharmaceuticals
Phase 2CCC
Siltuximab
Janssen Research & Development, LLC
Phase 1CC

View all 13 →

Same molecule, other indications

GLUCOSE, ANHYDROUS is also rated in:

Liver FailureDormant
BB
Indicative ·
68 / 100
View asset →
Critical IllnessDormant
BB
Indicative ·
67 / 100
View asset →
injuryDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →